Remus Pharmaceuticals Ltd vs Vilin Bio Med Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Remus Pharmaceuticals Ltd is ₹ 685.3 as of 30 Apr 15:30 . The P/E Ratio of Remus Pharmaceuticals Ltd is 49.4 as of March 2024 .The P/E Ratio of Vilin Bio Med Ltd is 0 as of March 2024 . The Market Cap of Remus Pharmaceuticals Ltd is ₹ 1016 crore as of March 2024 .The Market Cap of Vilin Bio Med Ltd is ₹ 0 crore as of March 2024 . The Dividend Payout of Remus Pharmaceuticals Ltd changed from 2.56 % on March 2023 to 4.44 % on March 2025 . This represents a CAGR of 20.15% over 3 yearsThe Dividend Payout of Vilin Bio Med Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.
Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs.
It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

About Vilin Bio Med Ltd

Vilin Bio Med Limited was originally incorporated on June 29, 2005, which commenced business on July 11, 2005 issued by Registrar of Companies, Andhra Pradesh, Hyderabad.
The Company started its first commercial production in 2006.
In 2007, the Company expanded the Phase 2 for Beta Lactum facility with 16000 sft for Tablet, Capsule and Dry Syrup sections.
In 2010, it acquired more than 1000 molecules Drug Approvals with different strengths in therapeutics of Diabetic, Neuro and Cardio. The Company added the Sachet section in Non-Beta Lactum facility in 2014.
The Company allotted a fresh issue of 40,00,000 Equity Shares of Rs 10/- each by its Initial Public Offering by raising funds aggregating to Rs 12 Crore on June 7, 2023. At present, Company is engaged in domestic business of manufacturing Pharmaceuticals products and the Manufacturing Unit is located in Roorkee, in the State of Uttarakhand.

FAQs for the comparison of Remus Pharmaceuticals Ltd and Vilin Bio Med Ltd

Which company has a larger market capitalization, Remus Pharmaceuticals Ltd or Vilin Bio Med Ltd?

Market cap of Remus Pharmaceuticals Ltd is 807 Cr while Market cap of Vilin Bio Med Ltd is 59 Cr

What are the key factors driving the stock performance of Remus Pharmaceuticals Ltd and Vilin Bio Med Ltd?

The stock performance of Remus Pharmaceuticals Ltd and Vilin Bio Med Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Remus Pharmaceuticals Ltd and Vilin Bio Med Ltd?

As of May 3, 2026, the Remus Pharmaceuticals Ltd stock price is INR ₹685.3. On the other hand, Vilin Bio Med Ltd stock price is INR ₹38.85.

How do dividend payouts of Remus Pharmaceuticals Ltd and Vilin Bio Med Ltd compare?

To compare the dividend payouts of Remus Pharmaceuticals Ltd and Vilin Bio Med Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.